Singapore markets closed

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.32-0.43 (-4.90%)
As of 11:41AM EDT. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

    BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024Location: NY, NYFireside Chat: 1:00 PM ET Event: Goldman Sachs 45th Annual Global Healthcare ConferenceDate: June 11

  • GlobeNewswire

    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

    Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in 2H of 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101

  • GlobeNewswire

    Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

    BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be app